FDA Estimates GSK Seizure Involves $4 Bil. Worth Of Product
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's seizure of GlaxoSmithKline's Paxil CR and Avandamet is the agency's largest in terms of monetary value, involving $4 bil. worth of product, the agency said
You may also be interested in...
GSK Paxil, Avandamet Seizure Will Have “Ripple Effect” On GMPs, FDAer Says
FDA hopes the seizure will serve as a warning to other manufacturers that do not heed guidelines for good manufacturing practices. The decision to bypass other regulatory options was made in consultation with Acting Commissioner Crawford. FDA is currently negotiating a consent decree with GSK.
NDAs, BLAs To Start Getting KASA Quality Risk Assessments After Successful Pilot With ANDAs
Internal review system reduces US FDA’s administrative work for OPQ risk assessments; agency’s standards will not change, and sponsors will not need to modify applications. Advisory committee endorses expansion, which will roll out to different application types over several years.
Expanded Access Cost Distribution: FDA Clarifies New Rules For Charging Patients
Revised draft guidance makes clear that sponsors may charge all patients a flat administrative fee to cover ‘startup’ costs, regardless of when they join.